Durability of immune responses to the BNT162b2 mRNA vaccine.

Antibody Formation BNT162 Vaccine COVID-19 / prevention & control COVID-19 Vaccines Humans Vaccines, Synthetic mRNA Vaccines

Journal

Med (New York, N.Y.)
ISSN: 2666-6340
Titre abrégé: Med
Pays: United States
ID NLM: 101769215

Informations de publication

Date de publication:
14 01 2022
Historique:
received: 03 11 2021
revised: 01 12 2021
accepted: 08 12 2021
entrez: 19 5 2022
pubmed: 20 5 2022
medline: 24 5 2022
Statut: ppublish

Résumé

Antibody responses to the Pfizer-BioNTech mRNA vaccine waned substantially 6 months after the second vaccination.

Identifiants

DOI: 10.1016/j.medj.2021.12.005 PMID: 35590141 PMC: PMC9304003
pubmed: 35590141
pii: S2666-6340(21)00406-2
doi: 10.1016/j.medj.2021.12.005
pmc: PMC9304003
mid: NIHMS1822573
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
Vaccines, Synthetic 0
mRNA Vaccines 0
BNT162 Vaccine N38TVC63NU

Types de publication

Letter Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

25-27

Subventions

Organisme : NIAID NIH HHS
ID : U19 AI090023
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI057266
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI057229
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI153559
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI167903
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148576
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests B.P. serves on the External Immunology Network of GSK and on the Scientific Advisory Board of Sanofi and Medicago. M.S. serves on the advisory board for Moderna.

Références

Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
PLoS Biol. 2018 Aug 10;16(8):e2006601
pubmed: 30096134
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356
Curr Protoc Immunol. 2020 Dec;131(1):e116
pubmed: 33215858
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Nature. 2021 Aug;596(7872):410-416
pubmed: 34252919

Auteurs

Mehul S Suthar (MS)

Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: msuthar@emory.edu.

Prabhu S Arunachalam (PS)

Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA.

Mengyun Hu (M)

Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA.

Noah Reis (N)

Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA.

Meera Trisal (M)

Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA.

Olivia Raeber (O)

Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford, CA, USA.

Sharon Chinthrajah (S)

Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford, CA, USA.

Meredith E Davis-Gardner (ME)

Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA, USA.

Kelly Manning (K)

Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA, USA.

Prakriti Mudvari (P)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Eli Boritz (E)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Sucheta Godbole (S)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Amy R Henry (AR)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Daniel C Douek (DC)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Peter Halfmann (P)

University of Wisconsin, Madison, WI, USA.

Yoshihiro Kawaoka (Y)

University of Wisconsin, Madison, WI, USA; National Center for Global Health and Medicine, Tokyo, Japan; University of Tokyo, Tokyo, Japan.

Scott D Boyd (SD)

Sean N. Parker Center for Allergy & Asthma Research, Stanford, CA, USA; Department of Pathology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.

Mark M Davis (MM)

Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA; Department of Pathology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.

Veronika I Zarnitsyna (VI)

Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA.

Kari Nadeau (K)

Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford, CA, USA; Sean N. Parker Center for Allergy & Asthma Research, Stanford, CA, USA.

Bali Pulendran (B)

Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA; Department of Pathology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: bpulend@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité active › Production d'anticorps › Durability of immune responses to the BNT162b2...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Vaccin BNT162 › Durability of immune responses to the BNT162b2...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Durability of immune responses to the BNT162b2...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Durability of immune responses to the BNT162b2...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Durability of immune responses to the BNT162b2...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Durability of immune responses to the BNT162b2...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Durability of immune responses to the BNT162b2...